Treatment recommendations for psoriatic arthritis by Ritchlin, C T et al.
Treatment recommendations for psoriatic arthritis
C T Ritchlin,
1 A Kavanaugh,
2 D D Gladman,
3 P J Mease,
4 P Helliwell,
5 W-H Boehncke,
6
K de Vlam,
7 D Fiorentino,
8 O FitzGerald,
9 A B Gottlieb,
10 N J McHugh,
11 P Nash,
12
A A Qureshi,
13 E R Soriano,
14 W J Taylor,
15 for the Group for Research and
Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
c Additional data
(supplementary appendix 1) are
published online only at http://
ard.bmj.com/content/vol68/
issue9
1University of Rochester
Medical Center, Rochester, New
York, USA;
2University of
California at San Diego, San
Diego, California, USA;
3University of Toronto, Toronto,
Ontario, Canada;
4Seattle
Rheumatology Associates,
Seattle, Washington, USA;
5Academic Unit of
Musculoskeletal and
Rehabilitation Medicine,
University of Leeds, Leeds, UK;
6Johann Wolfgang Goethe
University, Frankfurt, Germany;
7University Hospitals Leuven,
Leuven, Belgium;
8Stanford
University, Stanford, California,
USA;
9St. Vincent’s University
Hospital, Dublin, Ireland;
10Tufts
Medical Center, Boston,
Massachusetts, USA;
11Royal
National Hospital for Rheumatic
Diseases, Bath, UK;
12University
of Queensland, Cotton Tree,
Queensland, Australia;
13Harvard Medical School,
Boston, Massachusetts, USA;
14Hospital Italiano de Buenos
Aires, Buenos Aires, Argentina;
15University of Otago/
Wellington, Wellington, New
Zealand
Correspondence to:
C T Ritchlin, Clinical Immunology
Research Center, University of
Rochester Medical Center, 601
Elmwood Avenue, Box 695,
Rochester, New York 14642,
USA; christopher_ritchlin@
urmc.rochester.edu
Accepted 26 September 2008
Published Online First
24 October 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
ABSTRACT
Objective: To develop comprehensive recommendations
for the treatment of the various clinical manifestations of
psoriatic arthritis (PsA) based on evidence obtained from
a systematic review of the literature and from consensus
opinion.
Methods: Formal literature reviews of treatment for the
most significant discrete clinical manifestations of PsA
(skin and nails, peripheral arthritis, axial disease, dactylitis
and enthesitis) were performed and published by
members of the Group for Research and Assessment of
Psoriasis and Psoriatic Arthritis (GRAPPA). Treatment
recommendations were drafted for each of the clinical
manifestations by rheumatologists, dermatologists and
PsA patients based on the literature reviews and
consensus opinion. The level of agreement for the
individual treatment recommendations among GRAPPA
members was assessed with an online questionnaire.
Results: Treatment recommendations were developed
for peripheral arthritis, axial disease, psoriasis, nail
disease, dactylitis and enthesitis in the setting of PsA. In
rotal, 19 recommendations were drafted, and over 80%
agreement was obtained on 16 of them. In addition, a grid
that factors disease severity into each of the different
disease manifestations was developed to help the
clinician with treatment decisions for the individual patient
from an evidenced-based perspective.
Conclusions: Treatment recommendations for the
cardinal physical manifestations of PsA were developed
based on a literature review and consensus between
rheumatologists and dermatologists. In addition, a grid
was established to assist in therapeutic reasoning and
decision making for individual patients. It is anticipated
that periodic updates will take place using this framework
as new data become available.
The articular and dermatological manifestations
associated with psoriatic arthritis (PsA) are remark-
ably heterogeneous in the extent and type of tissue
involvement. Patients with PsA, a chronic systemic
inflammatory disorder, may develop not only
peripheral arthritis but also axial disease, dactylitis,
enthesitis and skin and nail psoriasis, with
consequent adverse impact on function and quality
of life (QoL).
12Heterogeneity is observed not only
in disease manifestations but also in severity and
course, which can vary from very mild psoriasis or
enthesitis to widespread psoriatic plaques, disfigur-
ing nail disease and severe joint inflammation with
destruction that can result in disability and
increased mortality.
34 Moreover, comorbidities
associated with psoriasis such as the metabolic
syndrome can contribute to damage in multiple
end-organs and often leads to markedly impaired
QoL as well as early mortality.
5–7
Recent progress in understanding the immuno-
pathogenesis of PsA has been accompanied by
treatment advances that have accelerated rapidly
over the last decade.
8 Despite these advances,
therapeutic decisions for an individual patient with
PsA can be challenging due to the diversity of
clinical characteristics and the simultaneous invol-
vement of multiple different tissues, often with
varying degrees of severity. To address the need for
evidence-based treatment recommendations and
assist the practitioner, members of the Group for
Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) published systematic reviews
of the literature to identify the best available
evidence regarding treatment of the various man-
ifestations of PsA.
19Herein, we present treatment
recommendations that were formulated by rheu-
matologists and dermatologists in GRAPPA in
conjunction with PsA patients, based on evidence
from these systematic reviews and consensus
opinion. These recommendations were developed
to provide the best care for patients with PsA,
regardless of economic or political considerations.
METHODS
The target audience for these treatment recom-
mendations is all clinicians who care for PsA
patients. First, formal literature reviews were
performed by members of GRAPPA. To capture
data regarding the varied areas of involvement
characteristic of PsA, articles were selected that
provided evidence supporting the treatment of
peripheral arthritis, spinal disease, skin and nail
disease, enthesitis and dactylitis in the setting of
PsA (fig 1). These articles were reviewed and
graded, and the results have been published.
10–16
The evidence was graded using the approach of the
Institute of Medicine.
17 Wherever possible, effect
sizes were calculated to quantify the extent of
efficacy or toxicity. Effect size is the mean
difference in effect between treatment and control,
divided by the standard deviation of the differ-
ence.
18 Effect sizes of 0.2 or less are considered
small and unimportant in terms of efficacy,
whereas effect sizes greater than 0.8 are considered
large and suggest high efficacy.
Reviewers graded the evidence and treatment
recommendations for PsA in accordance with
recommendations from the Agency for Health
Care Policy Research (AHCPR), as shown in table 1.
To address the nuanced and complex application
of the results of these studies to the heterogeneous
Recommendation
Ann Rheum Dis 2009;68:1387–1394. doi:10.1136/ard.2008.094946 1387situations that arise in the clinic, focus groups were assembled,
comprising experts in rheumatology and dermatology with
specific experience in the care of PsA and psoriasis and patients
with PsA. Next, subcommittees were formed for each of the five
domains, and recommendations were drafted based on evidence
and consensus between rheumatologists, dermatologists and
patients for psoriasis, peripheral arthritis, axial disease, dactylitis
and enthesitis. Each of these subcommittees developed a
definition of mild, moderate, or severe for their individual
domains. Finally, the subcommittee chairs met with AK and
CTR (authors) to refine the recommendations (mild–moderate–
severe categories) in each domain. The recommendations for
each domain and the grid with the three categories were voted
on by the entire membership of GRAPPA. Note that the grid
was designed as a tool to assist in making treatment decisions
for individual patients and as such is largely based on expertise.
Data that became available after the systematic reviews were
published were also considered by the various subcommittees.
A total of 19 items covering the diagnosis, assessment and
treatment of the 5 PsA clinical manifestations were submitted
for a vote using a web-based interface (Survey Monkey; http://
www.surveymonkey.com/). Each item was rated on a 5-point
scale (1=strongly agree to 5=strongly disagree). The
Disagreement Index (DI) was derived from the 30th and 70th
percentile of the respondents’ ratings, adjusted for symmetry
between the central point of the interpercentile range and the
mid-point of the rating scale. The adjustment factor was
derived from experimental work that compared different
definitions of what constituted ‘‘disagreement’’ among panels
of various sizes. The number of respondents, percentage
respondents in the 30th and 70th percentile, percentage
respondents in category 1 or 2, and the mean and standard
deviation were calculated.
RESULTS
The results of the survey are shown in the supplementary
material. In all, 70 rheumatologists and dermatologists
responded to the questionnaire. For 16 of the 19 items, 80%
of the respondents agreed or strongly agreed. The three areas
where agreement was not as strong included the use of the Bath
Ankylosing Spondylitis Disability Activity Index (BASDAI) to
measure axial disease activity over time (75.7%) and to assess
axial treatment response (78.7%) and the algorithm for the
treatment of psoriasis (69.2%). The strength of each recom-
mendation (grades A–D) is included.
Peripheral arthritis
Diagnosis and assessment
Diagnosis of PsA should follow the CASPAR (for Classification
Criteria for Psoriatic Arthritis) criteria.
19 We consider inflamma-
tion to include such features as pain involving joints, spine and/
or enthuses associated with erythaema, warmth and swelling;
prominent morning and rest stiffness.
Figure 1 Group for Research and
Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) treatment guidelines
for psoriatic arthritis, categorised by
disease characteristics and distinct organ
involvement. Anti-TNF, anti-tumour
necrosis factor; CsA, ciclosporin A;
DMARD, disease-modifying antirheumatic
drug; IA, intra-articular; LEF, leflunomide;
MTX, methotrexate; NSAID, non-steroidal
anti-inflammatory drug; PT,
physiotherapy; PUVA, psoralen–
ultraviolet light A; SSZ, sulfasalazine;
UVB, ultraviolet light B. Reproduced with
permission from Kavanaugh et al.
1
Table 1 Grading of evidence sources and recommendations
Evidence or recommendation Grade
Evidence source as recommended by the Agency for Health Care Policy Research (AHCPR):
Meta-analysis of randomised controlled trials (RCT) 1a
One or more RCT 1b
One or more controlled trials (without randomisation) 2a
Other well designed studies (quasiexperimental) 2b
Non-experimental studies (descriptive studies such as comparative or correlation studies, or case-control studies) 3
Expert committee opinions, clinical experience 4
Preliminary recommendations for treatment of psoriatic arthritis (using the best available evidence extracted from
published literature):
Category 1 evidence A
Category 2 evidence, or extrapolation from category 1 evidence B
Category 3 evidence, or extrapolation from category 1 or 2 evidence C
Category 4 evidence or extrapolation from category 2 or 3 evidence D
Recommendation
1388 Ann Rheum Dis 2009;68:1387–1394. doi:10.1136/ard.2008.094946Preferably, diagnosis of psoriasis should be confirmed by a
dermatologist and inflammatory musculoskeletal disease by a
rheumatologist, or either one by an appropriately qualified
health professional.
Baseline evaluations of PsA should include the following
domains (consensus on core set of domains for psoriatic arthritis
assessment established at the eighth Outcome Measures in
Rheumatology (OMERACT 8) conference, 2006).
20
c Peripheral joint assessment (68 joints for tenderness; 66
joints for swelling).
c Pain (patient-reported on a visual analogue or category
rating scale).
c Patient global assessment of disease activity.
c Physical function (eg, as measured by the Health
Assessment Questionnaire (HAQ)).
c Health-related QoL, as assessed by a general measure (eg,
Short Form 36 (SF-36)) or a PsA-specific measure (eg,
Psoriatic Arthritis QoL (PsAQoL)).
c Fatigue, measured by patient self-report or a general
instrument (eg, Functional Assessment of Chronic Illness
Therapy (FACIT)).
c Acute phase reactants (eg, C-reactive protein (CRP) or
erythrocyte sedimentation rate (ESR)).
Radiographic assessment is encouraged according to clinical
manifestation and doctor discretionary judgment.
Factors associated with a poor prognosis related to the
progression of peripheral joint disease and damage in patients
with PsA include: the number of actively inflamed joints (ie,
polyarticular disease, as opposed to monoarticular disease);
elevated ESR; failure of previous medication trials; the presence
of damage, either clinically or on x ray;
21 a loss of function as
assessed by HAQ; and diminished QoL as assessed by SF-36,
Dermatology Life Quality Index (DLQI), or PsAQoL.
A patient should be considered a treatment failure when in
spite of therapy for a length of time appropriate to the
pharmacokinetic/pharmacodynamic profile of the individual
agent at an appropriate dose, the patient fails to demonstrate
acceptable clinical improvement. Response to treatment of
peripheral arthritis in patients with PsA may be assessed using
criteria initially developed for rheumatoid arthritis (RA), such as
the 28-joint Disease Activity Score (DAS28, shown to be reliable
and discriminative in PsA, even though it uses only 28 joints)
and the European League Against Rheumatism (EULAR)
response criteria, which categorise levels of disease and changes
to assess response. The American College of Rheumatology
(ACR) percentage response criteria (eg, ACR20/50/70) may also
be used in PsA.
22 In a recent analysis of PsA and RA outpatient
cohorts,
23 the utility of the DAS28 for PsA was questioned with
regard to its applicability in settings outside of clinical trials,
where patients receive therapies of varying efficacy. Response
may also be considered inadequate if there is evidence of
progression of joint damage on radiographs.
Treatment
Treatment recommendations for peripheral arthritis include
non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular
glucocorticoid injections, disease-modifying antirheumatic
drugs (DMARDs) and TNF inhibitors (see table 2).
Systemic corticosteroids are not typically recommended in
the treatment of psoriasis and are only advisable in discrete
circumstances and not for chronic use, due to the potential to
cause post-steroid psoriasis flare and other adverse effects (D).
Gold salts, chloroquine and hydroxychloroquine also are not
recommended for use in PsA.
DMARDs have the potential to reduce or prevent joint
damage and preserve joint integrity and function (although
none have been shown to do this in PsA). Many factors
influence the choice of DMARD for the individual patient: its
relative efficacy, convenience of administration, requirements of
the monitoring program, costs of the medication and monitor-
ing (including doctor visits and laboratory costs), time until
expected benefit and the frequency and potential seriousness of
adverse reactions. Input from a rheumatologist is often essential
when initiating DMARD therapy.
A patient should be considered a DMARD failure if at least
one DMARD has been failed individually or in combination in
an adequate therapeutic trial, defined as treatment for
>3 months, of which >2 months is at standard target dose
(unless significant intolerance or toxicity limits the dose).
Intolerance/toxicity is defined as treatment for ,2 months,
where treatment is withdrawn because of drug intolerance or
toxicity. When treatment is withdrawn because of intolerance
or toxicity after .2 months therapy, at least 2 months should
have been at therapeutic doses.
Although there is no evidence for the use of combination
therapy, a combination of two or more agents could be used in
those patients who fail to respond to a single agent, or who
present joint damage progression in spite of treatment.
Axial disease
Diagnosis and assessment (based on ankylosing spondylitis (AS)
criteria)
Diagnosis of axial disease should be based on the presence of
two of three of the following criteria:
c Inflammatory back pain (features including onset age ,45
years, symptoms .3 months, morning stiffness .30 min,
insidious onset, improved with exercise, alternating buttock
pain).
c Limitation of motion of cervical, thoracic, or lumbar spine in
saggital and frontal planes; noted differences from AS
include less pain, less limitation in movement and less
symmetry. The International Spondyloarthritis Interrater
Reliability Exercise (INSPIRE) has shown assessments of
spinal disease in AS are also reliable in axial PsA.
24
c Radiological criteria (eg, plain x ray (unilateral sacroiliitis
grade 2 or more), syndesmophytes, MRI changes in
sacroiliac joints of bone marrow oedema, erosions, joint
space narrowing). Criteria modified from AS based on data
from Helliwell et al.
25
Based on experience in AS, disease activity in the spine can be
reliably measured by the BASDAI, where active disease has been
defined by a BASDAI score >4. The BASDAI can be used to
measure disease activity over time; assessment should take place
after 6 weeks of treatment. A treatment response, based on
definition of response in AS, is defined as a BASDAI score,3o r
a reduction by 2 points.
Treatment
See table 2 for treatment recommendations based on evidence
derived in AS. Traditional oral DMARDs such as methotrexate,
leflunomide and sulfasalazine, have not been shown to be
effective in axial manifestations of AS
26 and by extrapolation,
they are not considered to be of adequate efficacy for PsA axial
disease, until further data are available.
Recommendation
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Disease status Treatment recommendation Level of evidence* Level of agreement{ Comments
Peripheral arthritis Mild NSAIDs A 90.9% For control of joint but not skin symptoms
NA Intra-articular glucocorticoid
injections
D May be given judiciously to treat persistently
inflamed joints, if care is taken to avoid injection
through psoriatic plaques. Injections to any one
joint should be repeated with caution according
to clinical judgment
Moderate or severe DMARDs (specific
recommendations follow):
For all patients with severe or moderate
peripheral arthritis. Consider for mild disease if
patients do not respond to NSAIDS or intra-
articular steroids. No evidence supporting
DMARDs ahead of TNF inhibitors, although the
effect size for TNF inhibitors is much larger than
that for traditional DMARDs
Sulfasalazine
Leflunomide
Methotrexate
Ciclosporine
A
A
B
B
Moderate or severe TNF inhibitors A For patients who fail to respond to at least one
DMARD therapy. The three currently available
TNF inhibitors (etanercept, infliximab and
adalimumab) are equally effective for the
treatment of peripheral arthritis and for the
inhibition of radiographic progression. Patients
with poor prognosis could be considered for TNF
inhibitors even if they have not failed a standard
DMARD
Skin disease Moderate to severe Phototherapy A 69.2% First-line therapies:
Phototherapy includes UVB/nbUVB, oral PUVA,
bath PUVA, with or without acitretin. An initial
trial of phototherapy should be made, unless it is
not appropriate or if psoriasis is in areas that
preclude phototherapy (ie, scalp, groin, axilla). All
forms of phototherapy are considered as a group,
although many consider that PUVA therapy
carries increased risk of skin cancer compared
with other UV modalities. Aggressive
immunosuppression should not follow extensive
phototherapy (especially PUVA), given the
increased risk of melanoma and non-melanoma
skin cancer in this scenario
Methotrexate A
Fumaric acid esters A
TNF inhibitors A TNF inhibitors include etanercept, adalimumab
and infliximab
Efalizumab A
Ciclosporine A Ciclosporine should be limited to less than 12
consecutive months because cumulative toxicity
(ie, multiple courses) is not well studied
Acitretin A Second-line therapies
Alefacept A
Sulfasalazine A Third-line therapies
Hydroxyurea C
Leflunomide A
Mycophenolate mofetil C
Thioguanine C
Nail disease NA Retinoids C 69.2%
Oral PUVA C
Ciclosporine C
TNF inhibitors C TNF inhibitors include infliximab and alefacept
Spinal disease Mild to moderate NSAIDs A 86.4% For patients who fail therapies for mild to
moderate disease Physiotherapy A
Education, analgesia and injection
of sacroiliac joint
A
Moderate to severe TNF inhibitors A Infliximab, etanercept and adalimumab have all
demonstrated efficacy in AS; the consensus was
that similar treatment responses reported in AS
were also likely to be observed in axial PsA
Enthesitis Mild NSAIDS, physical therapy,
corticosteroids
D 87.9%
Moderate DMARDs D
Severe TNF inhibitors A Evidence has been demonstrated for infliximab or
for etanercept (in spondyloarthropathies)
Continued
Recommendation
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Diagnosis and assessment
The diagnosis of enthesitis is challenging; currently three
approaches have been described: clinical examination, including
pain/tenderness/swelling at tendon, ligament or capsule inser-
tion site by palpation and pressure; ultrasound with power
Doppler; and MRI.
Several instruments proposed for clinical assessment of
enthesitis have been tested in the INSPIRE study and were
reliable in AS and PsA, but no single instrument has gained
widespread acceptance.
24 Another assessment modality is the
visual analogue pain scale.
Treatment
See table 2 for treatment recommendations for mild, moderate,
or severe enthesitis.
Skin and nails
Diagnosis and assessment (for selection of topical vs systemic
therapy)
For patients with mild psoriasis, candidates for topical therapy
alone must meet all of the following criteria: generally
asymptomatic; minimal impact on QoL; amenable and respon-
sive to localised therapy; less than 5% for plaque psoriasis; and
no incapacity and/or disability. For patients with moderate to
severe psoriasis, candidates for an addition or change to
systemic and/or phototherapy should meet at least one of the
following criteria: symptomatic (ie, pain, bleeding, itching);
more than minimal impact on QoL; inadequate response to
localised therapy; body surface area generally greater than 5%
for plaque psoriasis; patients with guttate, erythrodermic, or
pustular psoriasis; psoriasis in vulnerable areas (face, genitals,
hands/feet, nails, scalp, or intertriginous areas); or varying
degrees of incapacity and disability from psoriasis.
Treatment
See table 2 for a list of first-line, second-line and third-line
systemic therapies for treatment of psoriasis.
It is important to note that the clinician should consider all
agents in a treatment level before proceeding to ‘‘lower’’ level.
Situations rendering a specific therapy as ‘‘not appropriate’’
include lack of response, adverse events and poor access to
therapy.
Unusual clinical subsets of psoriasis can co-occur with
arthritis; thus, treatment may vary from that used in psoriasis
vulgaris. For erythrodermic/generalised pustular psoriasis, con-
sider acitretin as first-line therapy, although more research is
needed. For palmoplantar pustuolosis, acitretin and oral PUVA
appear to result in improvement (no evidence for either one
being superior), with combination of the two providing superior
response. Ciclosporine and tetracycline appear to be of modest
benefit. No strict recommendations can be given, due to lack of
definition of treatment response, lack of controlled studies in
this area.
27 For treatment of hand/foot psoriasis, consider topical
PUVA, soriatane, efalizumab as preferable first-line agents
although more research is needed in this area.
All three TNF inhibitors have shown efficacy in phase 3
randomised controlled trials, but no head-to-head trials have
been published to directly compare efficacy and safety. Some
data, however, suggest that etanercept may not be as effective
in patients with high BMIs.
15 In psoriasis studies, etanercept
efficacy was dose-dependent, with doses as high as 100 mg per
week (double the typical dose for RA and PsA patients)
providing the most benefit.
28
The efficacy of therapies for psoriatic nail disease is not well
studied; see table 2 for existing evidence.
29 Specific recommen-
dations cannot be made due to size of studies and lack of
appropriate controls.
At this time, no recommendation can be given regarding
efficacy and side effect profiles of systemic corticosteroids
because clinical trial data are not available. In general,
monotherapy with systemic corticosteroids is to be avoided in
psoriasis because skin disease can flare during or after taper.
Further studies, however, are needed to evaluate the role of
short-term corticosteroids in severe, pustular and erythrodermic
psoriasis.
Dactylitis
Diagnosis and assessment
Dactylitis, defined as uniform swelling of a digit, is due to
synovitis, tenosynovitis and enthesitis together with soft-tissue
oedema. Dactylitis occurs in 16–48% of cases of PsA, and acute
dactylitis has been shown to be a clinical indicator of disease
severity in PsA.
30 Conversely, chronic, non-tender diffuse
dactylitic swelling may be less clinically significant, although
MRI appearances differ only quantitatively from acute dacty-
litis. Recurrent isolated dactylitis, often in the same digit(s),
may be the only clinical manifestation of PsA.
Treatment
The treatment of dactylitis is largely empirical. See table 2 for
treatment recommendations of initial and more resistant cases.
Severity assessment in PsA
Patients may be roughly stratified in categories of ‘‘mild’’,
‘‘moderate’’, or ‘‘severe’’ for peripheral arthritis, skin disease,
spinal disease, enthesitis and dactylitis according to presence of
criteria noted in table 3. This table is designed to be used as a
tool to assist in decision making, and rigorous adherence to the
proposed stratification is not appropriate. Until numeric
Table 2 Continued
Disease status Treatment recommendation Level of evidence* Level of agreement{ Comments
Dactylitis NA NSAIDs D 90.2% Usually employed initially
NA Corticosteroids D Many clinicians rapidly progress to injected
steroids
Resistant DMARDs D Nearly always in the context of co-existing active
disease
NA Infliximab A Some evidence available
*See Methods section of manuscript for description of categories and levels of evidence.
{Percentage of survey responders who agreed or strongly agreed (see supplementary material).
AS, ankylosing spondylitis; DMARD, disease-modifying antirheumatic drug; NA, not applicable or not specifically defined; NSAID, non-steroidal anti-inflammatory drug; PsA,
psoriatic arthritis; PUVA, psoralen–ultraviolet light; TNF, tumour necrosis factor; UVB, ultraviolet B light.
Recommendation
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instruments are validated, doctor judgment is required to
appropriately stratify individual patients. Some patients may
have multiple manifestations, and treatment decisions may be
determined by the most severe clinical presentation. The
synergistic impact of multiple simultaneous manifestations
may be assessed with the patient global assessment, HAQ and
disease-specific instruments (DLQI, PsAQoL). Two case descrip-
tions are provided in table 4.
DISCUSSION
The array of disease manifestations coupled with the wide range
in disease severity and course observed in PsA present
formidable challenges to the treating clinician. Therapeutic
decisions must be based on thorough assessments of the
different areas of involvement including the skin and nails. Of
note, the cumulative negative impact of widespread inflamma-
tion at various sites can be multiplicative, leading to profound
impairment of patient quality of life and function. Further
complicating treatment decisions are the paucity of adequately
powered placebo-controlled clinical trial data for some of the
most common agents used in the treatment of PsA, most
notably methotrexate. Certainly, the development of improved
trial design that incorporates relevant and measurable outcomes
favours biological agents since many of the older studies
conducted on DMARDs are under-powered and suffer design
flaws. Lastly, management of PsA often requires input from
rheumatology and dermatology: any treatment recommenda-
tions must be developed based on input from groups of doctors
as well as their patients.
31 32
The GRAPPA organisation was founded with the mission to
improve the care of PsA patients based on input from all doctors
and health professionals who care for PsA patients.
1 The GRAPPA
Treatment Recommendations Committee received expert opi-
nion from over 16 dermatologists; indeed, the psoriasis treatment
section of this paper was developed entirely by these doctors. Of
note, however, these dermatologists focused on the treatment of
psoriasis in the setting of PsA; therefore, their recommendations
should not be extrapolated to psoriasis alone. The section on
psoriasis treatment was also broadened to include some unusual
subsetsthatcanbeparticularlyvexingforthetreatingdoctorwith
regard to diagnosis and management.
The therapeutic strategies outlined in this manuscript
represent the first treatment recommendations based on a
thorough review of the literature, followed by a consensus
exercise among international dermatology and rheumatology
experts who care for PsA patients. Input from PsA patients
provided the doctors with a deeper understanding and
appreciation of how treatment options and decisions are viewed
Table 3 Disease severity
Mild Moderate Severe
Peripheral arthritis ,5 joints
No damage on x ray
No LOF
QoL minimal impact
Pt. evaluation mild
>5 joints (S or T)
Damage on x ray
IR to mild Rx
Mod LOF
Mod impact on QoL
Pt. evaluation moderate
>5 joints (S or T)
Severe damage on x ray
IR to mild–moderate Rx
Severe LOF
Severe impact on QoL
Pt. evaluation severe
Skin disease BSA,5, PASI,5, asymptomatic * Non-response to topicals, DLQI, PASI,10{ BSA.10, DLQI.10
PASI.10
Spinal disease Mild pain
No loss of function
Loss of function or BASDAI.4{ Failure of response
Enthesitis 1–2 sites
No loss of function
.2 sites or loss of function Loss of function or.2 sites and failure of response *
Dactylitis Pain absent to mild
Normal function
Erosive disease or functional loss Failure of response
*See case 1 in table 4; {see case 2 in table 4.
S, swollen; T, tender; LOF, loss of physical function; IR, inadequate response; BSA, body surface area; BASDAI, Bath Ankylosing Spondylitis Disability Activity Index; PASI, Psoriasis
Activity Severity Score; QoL, quality of life; DLQI, Dermatology Life Quality Index.
Table 4 Case descriptions
Case History/symptoms Recommendation(s)
1 19-year-old male student:
History of psoriasis.
Presented with disabling bilateral Achilles tendonitis and right plantar fasciitis.
Unable to bear weight.
Initial treatment (without sustained relief) included two different NSAIDs, a 10-day course of oral
corticosteroids, physiotherapy and plantar fascia injection.
Symptoms have been present for 10 weeks.
Mild scalp psoriasis that is well controlled with topical agents.
This patient has severe enthesitis and mild skin disease (see
table 3), and he has failed therapies for mild and moderate
enthesitis; a TNF inhibitor should be considered.
2 34-year-old male:
Moderate to severe psoriasis since childhood.
2-year history of inflammatory back pain with unilateral grade 2 sacroiliitis on a plain film of the AP
pelvis; his BASDAI is 5.6.
Used topical agents and phototherapy for psoriasis; has been treated with two different NSAIDS and
an exercise program with no change in the BASDAI.
No loss of function but mild impairment in QoL.
Percentage of BSA with plaque is 5%, which is having a significant negative impact on QoL, more
than the back pain.
DLQI is 7.2.
This patient has moderate axial disease and moderate skin
involvement (see table 3). For his axial disease, it is
recommended that he have education, analgesia and
sacroiliac injection. For his skin disease, a systemic agent is
warranted. If the combination of axial and skin disease is
severely impairing QoL and/or function, a TNF inhibitor may
be considered
Recommendation
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these recommendations centre primarily on the lack of studies
with high levels of evidence. It should be noted that many of the
agents mentioned in these guidelines are not necessarily
approved by appropriate regulatory agencies for these indica-
tions; for example, fumarates are neither US Federal Drug
Authority (FDA) nor European Medicines Agency (EMEA)
approved (they are approved only in Germany) for the therapy
of plaque psoriasis, but there is sufficient high-grade evidence to
warrant their inclusion as a first-line therapy. In addition, while
the sample size of participating GRAPPA members seems
robust, this number represents less than half of the registered
members in the organisation. Although patient-reported out-
comes (physical function, QoL and fatigue) have been measured
and have shown positive results, particularly with TNF
inhibitors, they were not the focus of our guidelines, except as
part of composite scores (eg, the HAQ and patient global
assessment in the ACR scoring system). Finally, considerable
differences persist among the members regarding how to assess
severity for the various manifestations of PsA. While the group
did have over 80% agreement regarding the content of the
disease grid (table 3), it was with the understanding that this
tool represents a starting point that will be modified as new
trial data are published. The core domains and instruments for
use in clinical trials and in the care of PsA patients have been
identified by GRAPPA, and preliminary validation was obtained
through the OMERACT process.
33–35
Assessment and treatment of axial manifestations of PsA is
very challenging because of the paucity of data. By consensus, it
was agreed that ASAS guidelines be used.
36 The cut-off point for
the definition of moderate to severe disease activity in AS was
chosen by ASAS to be a BASDAI score >4. For BASDAI
response criteria, a 50% relative change or absolute change of 2
(0–10) with expert opinion of significant improvement was
chosen. However, this cut-off was formally validated by Cohen
et al
37 and Pavy et al
38 and represents an appropriate criterion to
borrow from AS for axial disease in PsA until further testing can
be performed prospectively in clinical trials.
Recent studies have shown that dermatologists and rheuma-
tologists can assess skin and joint disease with a surprising
degree of agreement and accuracy.
39 Similar studies have been
published for axial disease.
24 Efforts to develop instruments for
assessment of dactylitis and enthesitis are underway, and it is
anticipated that these will be tested for validity in the near
future.
24 40 Ultimately, a composite assessment tool that can be
applied in the office setting will allow clinicians to formulate
more informed treatment decisions for individual patients.
Interest in PsA has greatly intensified over the past several
years due to several factors including a better understanding of
disease mechanisms, improved clinical trial design and perhaps
most importantly, the arrival of effective and relatively safe
biological agents that have dramatically altered the treatment
paradigm. Currently, a host of new treatments are in the
pipeline, many of which will offer new and possibly less
expensive therapeutic options. It is anticipated that the
treatment recommendations outlined in this study will be
refined and serve as a template for the development of revised
PsA treatment updates as new data are released.
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